Clinical Trials Logo

Primary Tumor clinical trials

View clinical trials related to Primary Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT05038358 Recruiting - Primary Tumor Clinical Trials

Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms

CRC-ORGA2
Start date: December 12, 2022
Phase:
Study type: Observational

Colorectal cancer is the third most common cancer worldwide and its progression-free survival is still low, around 10 months. Thirthy to 50% of patients do not respond to chemotherapy upon initiation of treatment, suggesting that early development of chemoresistance mechanisms remains a major challenge. In order to better characterize these mechanisms, the aim is to develop a model of tumoroids derived from patients with a colorectal tumors prior to any systemic anti cancer treatment. This project will both allow us to study the role of the immunological microenvironment in chemoresistance and identify new predictive markers of tumor response. It will then serve to develop innovative personalized medicine strategies by targeting the newly identified mechanisms. This study should in fine help to improve the cancer patient's care.

NCT ID: NCT04492735 Recruiting - Metastatic Disease Clinical Trials

The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies

Start date: June 5, 2020
Phase:
Study type: Observational

Use of indocyanine green will augment the accuracy of identification and resection of both primary solid malignancies as well as their pulmonary metastases, where applicable We will conduct a prospective feasibility study of pediatric patients with solid malignancies with or without lung metastatases who present at the time of initial diagnosis or relapse. These patients will receive a targeted dye to aid in the resection of these metastases. We plan to assess ICG as it relates to: 1. Diagnostic accuracy using pathologic correlation as gold standard measure 2. Short and long term event free and overall survival

NCT ID: NCT02410174 Terminated - Clinical trials for Renal Cell Carcinoma

To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors

Start date: May 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of the use of stereotactic body radiotherapy (SBRT) for the treatment of the primary tumor in renal cell carcinoma (RCC) in medically inoperable patients and/or patients who refuse surgery. Standard treatment of RCC is surgery. A number of non-surgical treatments of RCC are also available, but are highly invasive and are associated with significant side effects. SBRT is a non-invasive, non-surgical treatment that requires tumor immobilization and image guidance in order to deliver a very precise, high-dose treatment. This trial will assess the use of SBRT to treat primary renal tumors by determining the maximum tolerated dose and toxicity. Subjects enrolled in this study will then be followed and evaluated for toxicity, serum chemistry, complete blood count, and urinalysis. In addition, they will undergo renal scans to assess the functionality of their renal tissue.

NCT ID: NCT02301858 Active, not recruiting - Lung Cancer Clinical Trials

Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases

Start date: December 2013
Phase: N/A
Study type: Interventional

The project aims to compare the histopathological and molecular characteristics of tumour tissue from metastases with similar analyses of the primary tumour in the lung, where it is available. The investigators will therefore perform analysis of blood samples if possible, to identify predictive markers in blood samples.

NCT ID: NCT01525745 Completed - Metastatic Cancer Clinical Trials

Randomized Study of Stereotactic Body Radiotherapy vs. Conventional Radiation for Spine Metastasis

Start date: January 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine how effective SBRT is compared to traditional radiation in treating the cancer that has spread to your spine and is causing pain. SBRT is delivered at a higher dose for a shorter period of time when compared to standard radiation therapy and the aim is to see if there will be an improvement both in pain control and your cancer It is not known whether SBRT is better or worse than current standard therapy. If you are selected to receive the experimental treatment in this research study, SBRT uses highly focused x-rays that deliver a single high dose to a specific area of the spine compared to conventional standard radiation over a period of 10 days which has been the standard proven treatment to help your condition. The investigators will also determine which treatment provides the most rapid pain relief with the least side effects. It is possible that SBRT may not be better or could be more toxic. The investigators will conduct quality of life assessments and pain scale index to assess how you are feeling once you have had the intervention.